This launch supports Lupin's ongoing expansion in the U.S. generics market and enhances its footprint in the oral anti-diabetic segment. Lupin operates globally, with a presence in over 100 markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results